34.01
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 34.01 | 07:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 34.01 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 18.69 - 46.46 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 34.01 | USD |
Period:
Draw Mode:
REGENXBIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.47B | 43.23M | 28.36M | $ 470.35M | $ 77.94M | 2.91 | 16.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 159.30k | 1.40% |
REGENXBIO News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 32.89 | 35.73 | 32.59 | 34.50 | 355,177 | 1.12 | 3.41% |
| 1 Month | 28.48 | 35.73 | 26.0301 | 32.14 | 376,783 | 5.53 | 19.42% |
| 3 Months | 21.70 | 35.73 | 18.69 | 26.07 | 416,129 | 12.31 | 56.73% |
| 6 Months | 26.68 | 35.73 | 18.69 | 26.90 | 412,939 | 7.33 | 27.47% |
| 1 Year | 28.715 | 46.46 | 18.69 | 30.55 | 429,435 | 5.30 | 18.44% |
| 3 Years | 38.93 | 54.97 | 18.69 | 35.29 | 422,822 | -4.92 | -12.64% |
| 5 Years | 20.65 | 85.10 | 18.69 | 41.27 | 451,264 | 13.36 | 64.7% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |